4D Molecular Therapeutics, Inc. — Investor Relations & Filings
Filings indexed
372
across all filing types
Latest filing
2026-05-07
Regulatory Filings
Country
US
United States of America
Listing
US
FDMT
4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on inventing and developing genetic medicines to treat large-market diseases with unmet medical needs. The company utilizes its proprietary Therapeutic Vector Evolution platform, which harnesses the power of directed evolution, to create customized and optimized adeno-associated virus (AAV) vectors. These engineered vectors are designed for targeted delivery and enhanced therapeutic efficacy. 4DMT's clinical pipeline is concentrated on developing transformative products for serious conditions in ophthalmology, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), and in pulmonology, including cystic fibrosis.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| S-3 - 4D Molecular Therapeutics, Inc. (0001650648) (Filer) | 2026-05-07 | English | |
| SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject) | 2026-03-26 | English | |
| 4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer) | 2026-03-24 | English | |
| 8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer) | 2026-03-18 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English |
Browse filings by year
10 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
12 filings
| |||||
| 43556189 | S-3 - 4D Molecular Therapeutics, Inc. (0001650648) (Filer) | 2026-05-07 | English | ||
| 33048949 | SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject) | 2026-03-26 | English | ||
| 33035777 | 4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer) | 2026-03-24 | English | ||
| 32979140 | 8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer) | 2026-03-18 | English | ||
| 31122967 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31122953 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31122926 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 31122912 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31123065 | 8-K Filing | 2026-01-26 | English | ||
| 12900117 | 4 | 2026-01-08 | English | ||
| 12900118 | 3 | 2026-01-08 | English | ||
| 12900120 | 8-K | 2026-01-07 | English | ||
|
2025
3 filings
| |||||
| 12900119 | 4 | 2025-12-24 | English | ||
| 12900122 | 3 | 2025-12-19 | English | ||
| 12900121 | 4 | 2025-12-19 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Avagenesis Corp.
Develops automated technology for isolating and enriching r…
|
VVA | CA | Manufacturing |
|
Avalon GloboCare Corp.
Develops cell-based immunotherapies and provides precision …
|
ALBT | US | Manufacturing |
|
AVECHO BIOTECHNOLOGY LIMITED
Develops human and animal health products using TPM® drug d…
|
AVE | AU | Manufacturing |
|
Avicanna Inc.
Commercial-stage international biopharma focused on evidenc…
|
AVCN | CA | Manufacturing |
|
Avidity Biosciences, Inc.
Develops a class of RNA therapeutics called Antibody Oligon…
|
RNA | US | Manufacturing |
|
Avivagen Inc.
Developed natural health products and feed additives; filed…
|
VIV | CA | Manufacturing |
|
Awakn Life Sciences Corp. (1169082 BC Ltd.)
Clinical-stage biotech developing novel therapeutics, inclu…
|
AWKN | CA | Manufacturing |
|
Axcan Pharma Inc.
Specialty pharmaceutical company focused on prescription th…
|
AXCA | CA | Manufacturing |
|
Axogen, Inc.
Develops and commercializes surgical solutions for peripher…
|
AXGN | US | Manufacturing |
|
Axsome Therapeutics, Inc.
A biopharmaceutical company developing therapies for centra…
|
AXSM | US | Manufacturing |
4D Molecular Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33060/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33060 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33060 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33060 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33060}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for 4D Molecular Therapeutics, Inc. (id: 33060)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.